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Composite endpoints combine several events within a single variable, which
increases the number of expected events and is thereby meant to increase the
power. However, the interpretation of results can be difficult as the observed
effect for the composite does not necessarily reflect the effects for the compo-
nents, which may be of different magnitude or even point in adverse directions.
Moreover, in clinical applications, the event types are often of different clinical
relevance, which also complicates the interpretation of the composite effect. The
common effect measure for composite endpoints is the all-cause hazard ratio,
which gives equal weight to all events irrespective of their type and clinical rele-
vance. Thereby, the all-cause hazardwithin each group is given by the sumof the
cause-specific hazards corresponding to the individual components. A natural
extension of the standard all-cause hazard ratio can be defined by a “weighted
all-cause hazard ratio” where the individual hazards for each component are
multiplied with predefined relevance weighting factors. For the special case of
equal weights across the components, the weighted all-cause hazard ratio then
corresponds to the standard all-cause hazard ratio. To identify the cause-specific
hazard of the individual components, any parametric survival model might be
applied. The new weighted effect measure can be tested for deviations from the
null hypothesis by means of a permutation test. In this work, we systemati-
cally compare the newweighted approach to the standard all-cause hazard ratio
by theoretical considerations, Monte-Carlo simulations, and by means of a real
clinical trial example.
KEYWORDS
clinical trials, composite endpoint, relevance weighting, time-to-event
1 INTRODUCTION
Composite endpoints combine several events of interest within a single time-to-first-event variable. By combining several
event types, the number of expected events is augmented, which decreases the variance and thereby increases the power.
Moreover, when the clinical effect of interest cannot directly be captured by a unique event outcome, several event types
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can be combined into a composite instead of formulating a multiple test problem for several primary event endpoints.1,2
A composite endpoint can thus be interpreted as a surrogate for a time-to-event endpoint assessing the clinically most
relevant type of event, eg, death. Generally, a surrogate should be highly correlated with the endpoint of primary interest
in order to be clinically meaningful.
The common effect measure for composite endpoints is the all-cause hazard ratio which is tested by means of the
logrank test or the Cox-model to include covariates.3 This approach is based on counts of the total number of observed
events and neglects the corresponding type of event. As a consequence, a major difficulty in the interpretation of clinical
trials with composite endpoints is that the effect for the composite endpoint does not necessarily reflect the effects for
the individual components.4-6 In clinical application, the component effects are often of different magnitude or can even
point in adverse directions. This problem becomes even more prominent, if the single endpoints forming the composite
are of different clinical relevance. In this case, the composite endpoint does not define a meaningful surrogate and is
not necessarily highly correlated to the endpoint of primary interest. Related guidelines therefore recommended not to
combine endpoints of different clinical severity.2,7,8 This claim, however, is unrealistic in practice. Fatal events (eg, cardiac
death and death from any cause) usually define the most relevant events from a patient point of view. Therefore, these
event types must be considered when defining the primary endpoint. On the other hand, fatal events are often relatively
rare, that is, the expected number of events is low. Therefore, a combination with other event types within a composite
would be helpful. However, any nonfatal event is clearly less relevant than death. For this reason, the current guideline
recommendations can hardly be implemented in practice. As an alternative to a composite endpoint approach, multistate
or, more specific, competing risk modeling allows to analyze multiple endpoints simultaneously.9,10 Through additional
assumptions on proportional baseline hazards or identical covariate effects across transitions, the power of a multistate
model is increased compared to distinct Cox-models.11 However, for the individual components of a composite endpoint
these assumptions are usually not fulfilled and, as a consequence, multistate or competing risk models most often do not
define a satisfactory option for this specific application. Therefore, methods are required, which ease the interpretation
of composite endpoints even if the components are of different clinical relevance.
The CAPRICORN Trial12 is an illustrative example to illustrate the pros and cons of composite endpoints in general
and the impact of components with different clinical relevance in particular. This trial investigated the long-term effi-
cacy of carvedilol regarding morbidity and mortality in patients with left ventricular dysfunction after acute myocardial
infarction. In this multicenter, randomized, double blind and placebo-controlled trial, patients were randomly assigned
to carvedilol or placebo in a 1:1 allocation. The originally planned primary endpoint was time to death from any cause.
The accrual time was given by 24 months, the minimal follow-up by 3 months. Thus, the observational period is given
by [0; 27). During a masked interim analysis, the Data Safety Monitoring Board noted that the overall mortality rate was
lower than anticipated and consequently, the study was likely to be seriously underpowered. Therefore, it was decided
to change the primary endpoint to a composite time-to-first-event endpoint given as time to death or cardiovascular
hospital admission. Thereby, it was intended to increase the number of events and thus augmenting the power of the
trial. Clearly, the component death has a higher relevance than the component cardiovascular hospital admission. There-
fore, it might be questioned whether a standard unweighted composite effect measure is suitable to judge the treatment
performance.
The new composite primary endpoint was tested at a two-sided significance level of 0.0225, whereas a level of 0.0025
was saved to test the original primary endpoint. With this extremely small fraction of the global significance level, it is of
course very unlikely to obtain a significant result and therefore this “saving” might be questioned. The trial was planned
to detect a hazard ratio for death of 0.77 with a power of 0.9 at the one-sided significance level of 0.0225. Recruitment was
planned to continue until 633 target events were observed which was assumed to require 1850 patients in total. After a
mean follow-up of 1.3 years and inclusion of 1959 patients, the target number of events was reached for the new composite
endpoint. The observed all-cause hazard ratio was given by ?̂?CE = 0.92 and failed significance by far (p= .148 > .0225),
compare.13 In contrast, the observed hazard ratio for death was given by ?̂?Death = 0.77 with a p-value of .0155. This shows
that the contribution of the less relevant component “cardiovascular hospital admission” indeed had shrunken the overall
composite effect. Note that for the CAPRICORN Trial,13 two-sided significance levels and p-values were reported. For the
sake of consistency within this manuscript, we report the corresponding one-sided significance levels and p-values here.
With knowledge of the observed results in mind, the most reasonable endpoint in this study would have been a single
endpoint given by “death.”However, this knowledgewas not available in the planning stage and during the ongoing study.
From a planning perspective, it seemed reasonable to add the additional component “cardiovascular hospital admission”
to potentially increase the power. However, at the same time, the influence of this new component should be limited as
RAUCH ET AL. 751
“death” clearly defines the clinicallymore relevant endpoint. For this reason, the unweighted all-cause hazard ratiomight
be difficult to interpret in this case.
A possible approach solving this problem is to directly define a weighted composite effect measure, where the weights
reflect the clinical relevance of the different components. By this, a treatment effect in the composite can no longer be
caused by a large effect in a component of low clinical relevance.When introducing relevanceweights for the components
of the composite endpoint, the resultingmodified surrogate endpoint is potentially clinicallymoremeaningful and higher
correlated to the endpoint of primary clinical relevance. Of course, even with a weighting approach, the treatment effect
of the composite allows no generalization on the treatment effects of the individual components. However, this issue
is less problematical if the composite really defines a clinically relevant endpoint, which truly reflects the effect of the
interventionunder investigation. For the specific application of theCAPRICORNTrial, a composite effectmeasure putting
a higher weight on the component “death” than on the less relevant component “cardiovascular hospital admission”
would be meaningful. By this, the negative impact of the less relevant component could be shrunken, which would ease
the interpretation of the net effect.
Several authors have proposed weighting strategies for composite endpoints. Duc and Wolbers14 recently presented a
weighting approach for testing absolute risk differences that defines an alternative effect measure for binary composite
endpoints. With respect to composite time-to-first-event endpoints, Pocock et al15 and Buyse16 proposed two similar con-
cepts referred as the “win ratio” and the “proportion in favor of treatment,” respectively, based on counting the number
of pairwise comparisons with a more favorable outcome in the intervention group. Thereby, the components of lower
importance only affect the comparison if the determination of the pairwise “winner” is not possible based on the compo-
nent of primary importance. Bebu and Lachin17 and Rauch et al18 showed that these effect measures are highly dependent
on the censoring distribution and are in particular influenced by competing risks. In addition, the influence of each
individual component on the combined effect depends on the follow-up duration. Péron et al19 proposed a modified pro-
portion in favor of treatment correcting for bias introduced by uninformative censoring. However, when investigating
several priority-ranked time-to-event outcomes, a competing risk situation arises, which corresponds to informative cen-
soring. Moreover, the influence of the follow-up duration on the component weights does remain an unsolved problem.
A further major disadvantage is that the computational effort for these effect measures becomes large if the underlying
sample sizes increase. Despite these unfavorable properties, the win ratio and the proportion in favor of treatment are
very present in the medical and in the statistical literature. Therefore, we will provide an exemplary simulation scenario
to illustrate the difference between these approaches and the newmethod presentedwithin this work. In addition, Lachin
and Bebu20 proposed a test based on a weighted average of the log-transformed component hazard ratios. In their origi-
nal approach, the component hazard ratios are not given by the cause-specific hazard ratios but by the individual hazard
ratio, which ignores the competing risk scenario. However, their approach can easily be adapted to the cause-specific haz-
ard ratios to account for competing risks. A potential drawback of the latter method is that the weighted average of the
log-transformed cause-specific hazards is not directly related to the common all-cause hazard ratio. Moreover, by weight-
ing the log-transformed cause-specific hazard ratios, the number of events for each component does not influence the
magnitude of the weighted effect measure but only its variance. By this, the weighted effect measure can be driven by
a large effect in an individual component even if the component effect is highly variable due to a small event number.
Finally, as the variance of the weighted average of the log-transformed cause-specific hazards is basically a weighted sum
of the individual component variances, the variance increases with increasing number of components. In contrast, a com-
posite endpoint combines several components with the aim to increase the number of events and thereby reducing the
variance.
To overcome the above problems, we propose a new weighted composite effect measure defined as the ratio between
the weighted averages of the cause-specific hazards for the two groups. This “weighted all-cause hazard ratio” defines
a natural extension of the standard all-cause hazard ratio as the weights are assigned to the individual cause-specific
hazards and not to the (log-transformed) cause-specific hazard ratios. In particular, if the weights for the individ-
ual components are equal, the new effect measure corresponds to the common all-cause hazard ratio. To estimate
the weighted all-cause hazard ratio, estimators for the underlying cause-specific hazard are required, which can be
obtained from any parametric survival model. In this work, we focus on the Weibull-model as the Weibull-distribution
allows to model various shapes of event time distributions. The need for a parametric survival model might be seen
as a potential drawback of our method. However, note that the commonly applied Cox-model to assess a compos-
ite endpoint is based on the assumption of proportional all-cause hazards. This is a very restrictive assumption as
the hazards of the individual components sum up to the hazard of the composite endpoint, which thus cannot both
be proportional between groups simultaneously, except for the case of equal baseline-hazards including the special
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case of constant hazards (exponentially distributed event times). This strong proportional hazard assumption for the
all-cause hazards is no longer required with our approach. Moreover, as the choice of the underlying parametric
model to identify the individual cause-specific hazards is arbitrary, we feel that this does not define a too strong
restriction.
This paper is organized as follows. In Section 2, the standard approach for quantifying and analyzing composite end-
points in terms of the all-cause hazard ratio and the logrank test will be introduced. In Section 3, we will shortly introduce
the concept of the win ratio and the proportion in favor of treatment as these weighting approaches are currently broadly
discussed in medical applications. Subsequently, the new weighted effect measure and a related test will be introduced
in Section 4. Sections 5 and 6 illustrate and discuss the pros and cons of all approaches by theoretical considerations and
by a simulation study based on a real clinical trial examples and on illustrative settings. We conclude with a discussion
in Section 7. The R code implementing the calculations required for the illustrating examples is provided as Supporting
Information to ease application in practice.
2 STANDARD APPROACH FOR A COMPOSITE ENDPOINT
Throughout this work, a two-arm clinical trial comparing a new intervention to a control is considered where the index I
denotes the intervention group and the index C is assigned to the control. The sample sizes in the intervention and the
control group are assumed to be equally given by n for the sake of simplicity. Note, however, that the generalization of
all presented methods to unequal group sizes is straightforward so this does not define a restriction. Moreover, it will be
assumed in the following that the occurrence of an event is harmful, that means a lower number of events corresponds
to a more favorable result. Furthermore, we will focus on the case where the aim is to demonstrate superiority of the new
treatment and a one-sided test problem is formulated. In this work, a composite endpoint consisting of k components
EPj, i = 1, . … , k is considered.
2.1 Effect measure
The individual components can be expressed in a competing risk model with k competing events.3 The components
are usually parametrized via the cause-specific hazards for the two groups 𝜆IEPj (t), 𝜆
C
EPj
(t), j = 1, … , k.3,21 The composite















is constant in time. The proportional hazard assumption is fulfilled if the hazard can be written in the common form of
the Cox-model given as
𝜆(t) = 𝜆0(t) · exp(𝜃 · X),
where 𝜆0(t) is the baseline hazard and X is the binary covariate expressing the group allocation. For the all-cause hazard
referring to the composite this means
𝜆CE(t) = 𝜆CE,0(t) · exp(𝜃CE · X), (2)
and for the cause-specific hazards referring to the individual components the proportional hazard assumption implies
that
𝜆EPj (t) = 𝜆EPj,0(t) · exp(𝜃EPj · X), j = 1, … , k. (3)
It is easily seen that (2) and (3) can only hold true simultaneously if the baseline hazards are equal across the
components, that is,
𝜆0 ∶= 𝜆CE,0(t) = 𝜆EPj,0(t), j = 1, .., k. (4)
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Note that (4) implies that the instantaneous risk to experience an event at time t in a given treatment group is the same
across all event types. However, as indicated above, fatal events usually occur only rarely whereas nonfatal surrogate
event types are commonlymuchmore frequent. Therefore, the common situation is that the baseline hazards for different
event types are not all equal and, as a consequence, the proportional hazard assumption is not fulfilled for all components
simultaneously. Despite the fact that (4) is usually not fulfilled, it is common practice to report the all-cause hazard ratio
for the composite and the cause-specific hazard ratios for the components as constant parameters.
2.2 Test problem and test statistic
The test hypotheses for a one-sided test problem formulated in terms of the all-cause hazard ratio are given as
H0 ∶ 𝜃CE ≥ 1 versus H1 ∶ 𝜃CE < 1. (5)
The standard test to assess the above hypotheses under proportional hazards is the logrank test. The score test version





















where d denotes the total number of observed events,Nll ,N
C
l are the numbers of patients at risk just before the ith observed
event (l = 1, … , d) in the intervention and the control group, respectively, and Ill is an indicator variable, which equals 1
whenever the event occurred in the intervention group. The denominator corresponds to the common variance estimator
from the Cox-model. Under the null hypothesis given in (5), the test statistic (6) is approximately standard normally dis-
tributed, where negative values of the test statistic favor the intervention.23 Thus, the null hypothesis is rejected whenever
LR ≤ −z1−𝛼 , where z1−𝛼 is the corresponding (1 − 𝛼)-quantile of the standard normal distribution and 𝛼 is the one-sided
significance level.
3 CURRENT WEIGHTED APPROACHES FOR COMPOSITE ENDPOINTS
The “proportion in favor of treatment” is a new effect measure for prioritized outcomes which was introduced by Buyse.16
First, the individual components are ranked according to their clinical relevance starting with themost relevant endpoint.
Then, each patient in the intervention group is compared to each patient in the control group which results in a total of
n2 pairwise comparisons. The favor function f(ps) indicates the result of a comparison for a given pair ps, s = 1, … ,n2
as follows: First, the patient with the more favorable outcome with respect to the component of primary priority is deter-
mined. If no decision can be drawn due to censored observations, the comparison is based on the component of secondary
priority and so on. If the patient from the intervention group is superior to the patient from the control group the favor
function is set to f(ps) = 1, whereas if the patient from the control group shows a better outcome then the favor function is
set to f(ps) = −1. If no decision for any of the endpoints is possible due to censored observations, the comparison between
two patients is said to be “uninformative” and the favor function is set to f(ps) = 0. The proportion in favor of treatment
is then defined as
Δ ∶= E (f (ps)) ∈ [−1; 1],






The one-sided test problem to be assessed in confirmatory analysis is then given by
HCE0 ∶ Δ ≤ 0, versus HCE1 ∶ Δ > 0.
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Buyse16 proposed to assess these hypotheses by a permutation test. Note that this test strategy requires a substantial
computational effort as calculating the point estimator Δ̂ already implies the investigation of n2 pairwise comparisons and
the permutation test requires to repeat this step for a large number of times. A more detailed mathematical description
of this effect measure and the related test strategy was provided by Rauch et al.18
The win ratio introduced by Pocock15 is similar to the proportion in favor of treatment presented above. In contrast to
the proportion in favor of treatment, however, the win ratio was originally introduced for a matched-pair design where
matching is done according to independent risk variables and thus there are only a total of n pairs to be compared. Using











) ∈ [0;∞), (7)
where 1{∗} is an indicator function, which indicates whether the comparison for the ith matched pair is positive or neg-
ative, respectively. The win ratio is thus defined as the expected number of “winners” divided by the number of “losers.”
It can be estimated by replacing the expected numbers by the observed frequencies. Large values of 𝛹 favor the inter-
vention. As the matched-pair design is rather uncommon in clinical applications, we focus on the proportion in favor of
treatment as the reference procedure within this work.
Several authors have shown that the proportion in favor of treatment and thewin ratio highly depend on the underlying
censoring distribution.17,18 Moreover, Rauch et al18 provided extensive exemplary settings to illustrate the strong depen-
dence of this effect measure on the follow-up duration. The magnitude of the observed value Δ̂ is therefore difficult to
interpret. In addition, it can easily be shown that the favor function f does not define a transitive relation between two
observations meaning that if patient A wins over patient B, and patient B wins over patient C, this does not imply that
patient A also wins over C. Rauch et al18 therefore came to the conclusion that the above effect measures should not be
used in the presence of censoring, which is the standard situation in a time-to-event setting. However, as the proportion
in favor of treatment and the win ratio are so prominently discussed within the medical and statistical literature, we will
include a comparative simulation study using the proportion in favor of treatment as an additional reference procedure.
4 NEW WEIGHTED APPROACH FOR A COMPOSITE ENDPOINT
The idea of theweighted approach is to define a new composite effectmeasure that weights the influence of the individual
components by their clinical relevance. In general, there are variousways to combineweighted components in a composite
measure, compare, eg, the related works15,16,20 discussed in Section 1. None of these approaches is directly related to the
common all-cause hazard ratio defined in (1).
4.1 Effect measure




wj · 𝜆IEPj (t)∑k
j=1
wj · 𝜆CEPj (t)
, (8)
where wj ≥ 0, j = 1, … , k are nonnegative weighting factors reflecting the clinical relevance of EPj. For equal weights
w1 = w2 = ... = wk the weighted all-cause hazard ratio corresponds to the standard all-cause hazard ratio. The weighted
all-cause hazard ratio can also be interpreted as the standard all-cause hazard ratio based on modified component
distributions that are parametrized via the modified cause-specific hazards
?̃?EPj (t) ∶= wj · 𝜆EPj (t), j = 1, … , k.
This property is appealing, as the weighted effect measure thus defines a natural extension of the commonly applied
all-cause hazard ratio. To ease the interpretation, the weighted all-cause hazard ratio can also be written as the standard
hazard ratio multiplied by a weight-dependent factor




wj · 𝜆IEPj (t)∑k
j=1













The weighted all-cause hazard ratio is a time-dependent effect measure as long as the cause-specific hazards have no
common baseline-hazards. It can thus either be reported for a predefined reasonable time point t or, as an alternative,







where [0, f] defines the observational interval.
Simple plug-in estimators for 𝜃wCE(t) and Θ
w
CE(f ) can be obtained by means of the estimators for the underlying
cause-specific hazards. The latter can be obtained from any parametric survival model. In this work, we focus on the




the corresponding estimates of the hazard functions resulting from the correspondingWeibull-models, then an estimator




wj · ?̂?IEPj (t)∑k
j=1
wj · ?̂?CEPj (t)
. (11)
If the cause-specific hazards can reasonably be assumed to have the same baseline-hazard 𝜆0(t), compare (2) to (4), an
alternative nonparametric estimator for 𝜃wCE(t) can be derived using the representation of the weighted all-cause hazard
















, j = 1, … , k. (12)
The latter expression is a ratio of the cumulative hazards over timewhich can be nonparametrically estimated bymeans













where ?̂?CE defines the estimator for the all-cause hazard ratio from the common Cox-model. Generally, the components
of a composite hazard usually do not correspond to the same baseline-hazards as the instantaneous risk to experience
an event at time t differ between events of different type. Therefore, we focus on the parametric estimator (11) in the
remainder of this work.
Both estimators (11) and (13) are consistent as the nominator and the denominator of (11) and (13) are both continuous
functions of consistently estimated parameters which are thus also consistent by the continuousmapping theorem. As the
denominator converges to a constant, applying Slutky's theorem yields the consistence, compare Lehmann.24 A consistent
estimator Θ̂wCE(f ) can be defined equivalently.
4.2 Test hypotheses and test statistic
The test problem to be assessed in the confirmatory analysis in terms of the weighted all-cause hazard ratio are given as
HCE0 ∶ 𝜃
w
CE(t) ≥ 1 versus HCE1 ∶ 𝜃wCE(t) < 1. (14)
Equivalently, the test hypotheses can be formulated in terms of the integrated weighted all-cause hazard ratio
HCE0 ∶ Θ
w
CE(f ) ≥ 1 versus HCE1 ∶ ΘwCE(f ) < 1. (15)
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A potential drawback of our approach is that the variance of the estimators ?̂?wCE(t) and Θ̂
w
CE(f ) cannot directly be deduced
and therefore the asymptotic distributions are unknown. In order to overcome this problem, the above hypotheses can be
assessed by means of a permutation test. The R source code for the corresponding permutation test is provided as Sup-
porting Information, so application in practice is straightforward. Note that the knowledge of the underlying distribution
is an important advantage of the weighted approach proposed by Lachin and Bebu20 as the variance of the weighted aver-
age of the log-transformed cause-specific hazard ratios is a weighted sum of the variances of the cause-specific hazard
ratios. However, according to the arguments presented in the introduction, our approach provides important interpreta-
tion advantages and therefore the choice of the weighted effect measure should not only be guided by the existence of a
parametric statistical test.
4.3 Considerations on the choice of weights
An important aspect of an adequate andmeaningful analysis using aweighted composite effectmeasure is that theweights
must be prespecified in the planning stage. In principle, the relevance weighting factorswj > 0, j = 1, … , k can be chosen
completely freely without any restriction. The magnitude of these factors should thereby reflect the relative importance
of the components to each other. Note that the influence of an individual component on the weighted effect measure
becomes higher if the corresponding weight is large, but also if the underlying cause-specific hazard is large. Therefore,
components referring to higher hazards are naturally up-weighted. A very small hazard caused by a low number of events
will thus only influence the overall weighted effect if the relevance weighting factor is extremely large. In general, the
largest weights should be assigned to the most harmful events such (e.g. fatal events). However, the specific clinical trial
situationhas always to be taken into account.As illustrated above, theweighted all-cause hazard ratio can be interpreted as
the standard all-cause hazard ratio based on alternative component distributionswhich are parametrized via themodified
cause-specific hazards. Recalling the planning situation of the CAPRICORN Trial,12 we consider two types of events,
namely, "death" and "cardiovascular hospital admission". From a clinical perspective, it seems reasonable to assign a
higher weight to the more relevant component "death" and a lower weight to "cardiovascular hospital admission". As
"death" is much more relevant than "cardiovascular hospital admission", we choose the following weights
wDeath = 0.9,wHospital = 0.1.
The question is now how the components weights modify the underlying true event time distributions. The reported
observed results of the CAPRICORNTrial published in13 comprised the all-cause hazard ratio for the composite endpoint,
the cause-specific hazard ratio for death as well as the underlying observed event frequencies. From these results, we










The estimated event time distributions of the composite and the individual components are thus given as
SICE = 1 − exp(−0.0276 · t),
SCCE = 1 − exp(−0.0299 · t),
SIDeath = 1 − exp(−0.008 · t),
SCDeath = 1 − exp(−0.0104 · t),
SIHospital = 1 − exp(−0.0196 · t),
SCHospital = 1 − exp(−0.0195 · t).
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The modified event time distributions of the composite and the individual components are then given as
SICE = 1 − exp(−(0.9 · 0.008 + 0.1 · 0.0196) · t) = 1 − exp(−0.00916 · t),
SCCE = 1 − exp(−(0.9 · 0.0104 + 0.1 · 0.0195) · t) = 1 − exp(−0.01131 · t),
SIDeath = 1 − exp(−0.9 · 0.008 · t) = 1 − exp(−0.0072 · t),
SCDeath = 1 − exp(−0.9 · 0.0104 · t) = 1 − exp(−0.00936 · t),
SIHospital = 1 − exp(−0.1 · 0.0196 · t) = 1 − exp(−0.0196 · t),
SCHospital = 1 − exp(−0.1 · 0.0195 · t) = 1 − exp(−0.0195 · t).
The original and the modified event time distributions of the composite endpoint are also displayed in Figure 1.
It can be seen that the event time distribution curves for the intervention and the control group are relatively close
for the unweighted approach whereas the curves are more distinguished for the weighted approach. As the weights are
chosen to be smaller than 1, theweighted curves are generally shifted upwards. Note, however, that theweighted all-cause
hazard ratio is a relative effect measure and hence the distance between the curves and not the position of the curves
influences the overall effect. For the specific application of the CAPRICORNTrial, the proposedweights will thus increase
the power compared to the standard all-cause hazard ratio approach as the more relevant component also corresponds to
the higher effect.
However, theweighted all-cause hazard ratio can also result in a loss of power compared to the standard all-cause hazard
ratio whenever the most relevant components show the smallest effects, which often is the case in medical applications.
The rationale to use the weighted approach is thus not to increase power but to improve the clinical interpretation of the
overall effect. In the latter case, the unweighted all-cause hazard ratiowould suggest a too optimistic effect,which is impor-
tantly driven by a component of low clinical relevance. The RENAAL Trial25,26 presented in Section 6 is an illustrative
example for such a situation. These potentially conflicting interests in increasing the power and improving interpretation
might impose the question how large the weights for the most relevant components can be chosen without too much
loss in power. These considerations can be interpreted as a kind of “risk-benefit assessment.” On the one hand, the aim
is to provide a meaningful combined effect measure, which assigns higher weights to the more relevant components, on
the other hand the weight must be chosen such that the less relevant components still contribute to the overall power to
reach feasibility of the trial. Therefore, we recommend to choose some starting values for the weights based on external
relevance criteria, eg, from a discussion with clinicians. Subsequently, the power related to the weighted all-cause hazard
ratio under the given planning assumptions should be investigated by simulations. If the achieved power is too small, the
weights are adjusted such that (1) the magnitude of the weights still reflects the clinical relevance and (2) the power loss
is acceptable. This approach is illustrated for the RENAAL Trial25,26 in Section 6. If no such weight constellation can be
found, the sample size must be increased to guarantee both a powerful and a meaningful endpoint.
Generally, weighted combined effect measures are often criticized as the choice of the weights remains to a certain
extent arbitrary. Although this criticism is in principle correct, it should also be kept in mind that the use of a composite
time-to-first-event endpoint always refers to an implicit weighting of the components as the components, which corre-
spond to a higher number of observed events have a higher influence on the combined net effect. Therefore, using the
standard all-cause hazard ratio can also be criticized for an arbitrary implicit weighting of the components. It may there-
FIGURE 1 Event time distributions for the composite endpoint based on original hazards (left) and modified weighted hazards (right)
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fore even be seen as a more objective strategy to assign predefined relevance weights instead of weighting exclusively
by the amount of randomly observed event types. Independent of the chosen approach, whenever several time-to-event
endpoints are combined within a single effect measure, there is no fully objective way to do so.
4.4 Possible extensions
The weighted all-cause hazard ratio 𝜃wCE can also be estimated based on covariate-adjusted estimates of the cause-specific
hazards. It is also possible to include hazards estimates for the transition between a first and a second event or between
any subsequent events. This has the advantage not to waive the information resulting from subsequent events occurring
after the first. Unless for large cohort studies, the sample size of an interventional randomized, controlled trial is usually
limited and thus the number of subsequent events is also limited, especially when differentiating between the different
event types. As a consequence, the corresponding transition hazards will be small and therefore their impact on the
magnitude of 𝜃wCE is usually limited.
5 COMPARISON OF THE DIFFERENT EFFECT MEASURES
5.1 Comparison of the weighted and standard all-cause hazard ratio
To provide a systematic comparison between the standard and the new weighted approach, we begin by investigating the
true treatment effects for given event time distributions and predefined component weights. For ease of representation,
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The choice of Weibull-distributions is motivated by the fact, that they are able to flexibly model a variety of different
distribution forms—in particular those distributions fulfilling the proportional hazards assumption and those who do
not. To provide a wide range of distribution forms, the 5 parameter constellations provided in Table 1 will be considered.
These 5 scenarios cover in particular the cases of constant hazards (scenarios 1 and 2), increasing hazards (scenario 3),
and decreasing hazards (scenarios 4 and 5) over time. Moreover, the parameters of the Weibull-distributions are chosen
such that the impact of the weights on the weighted cause-specific hazard ratio becomes obvious. Note that scenario 5
differs from scenario 4 in that the group-specific hazards of EP2 are reversed. Thus, for scenario 5, the endpoints EP1 and
EP2 show opposite effects.
The corresponding event time curves, the hazards, and the related (weighted) hazard ratios are displayed in Figures 2
and 3. The left part of Figures 2 and 3 shows the corresponding event time curves. The plot in the middle shows
the underlying cause-specific hazards for EP1 and EP2 as functions in time. Finally, the plots on the right-hand side
show the cause-specific hazard ratio for each endpoint, the standard all-cause hazard ratio that equals the weighted
all-cause hazard ratio with common weights (here w1 = w2 = 0.5), and the weighted all-cause hazard ratios for weights
w1 = 0.8,w2 = 0.2 andw1 = 0.2,w2 = 0.8, favoring either EP1 or EP2, respectively. Throughout this manuscript, we report














1 0.9 1.0 1.0 1.0 0.4 1.0 0.8 1.0
2 0.1 1.0 0.6 1.0 0.15 1.0 0.2 1.0
3 0.3 1.4 0.8 1.0 0.15 1.3 0.2 1.0
4 0.3 0.8 0.8 1.0 0.1 0.9 0.15 1.0
5 0.3 0.8 0.8 1.0 0.15 1.0 0.1 0.9
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the cause-specific hazard ratios as reference values for the component effects. Note, however, that the cause-specific haz-
ard ratios are not directly related to the (weighted) all-cause hazard ratio and therefore a comparison of the composite
effect to the component effects should be done with care.
Table 2 reports the differentweighted all-cause hazard ratios 𝜃wCE(t) at times t = 1∕3·f, 2∕3·f, f and the averagedweighted
all cause-hazard ratio ΘwCE(f ) for an observational period of f = 5 years for different prespecified weights w1 = w2 = 0.5,
w1 = 0.8,w2 = 0.2 and w1 = 0.2,w2 = 0.8. For the sake of comparison, the cause-specific hazard ratios 𝜃EPi (5), i = 1, 2,
are also provided. Note that the weighted all-cause hazard ratio is equivalent to the standard all-cause hazard ratio for the
case of equal weights across the components.
FIGURE 2 Event time distributions (left), corresponding cause-specific hazards (middle), and (weighted) hazard ratios (right) as functions
in time for scenarios 1 to 3
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FIGURE 3 Event time distributions (left), corresponding cause-specific hazards (middle), and (weighted) hazard ratios (right) as functions
in time for scenarios 4 and 5
TABLE 2 Comparison of different effect measures for scenarios 1 to 5
Scenario w1 w2 𝜽EP𝟏 (𝟓) 𝜽EP𝟐 (𝟓) 𝜽
w
CE(𝟏 ∕ 𝟑 · 𝟓) 𝜽
w
CE(𝟐 ∕ 𝟑 · 𝟓) 𝜽
w
CE(𝟓) 𝚯wCE(𝟓)
1 0.5 0.5 0.9 0.5 0.722 0.722 0.722 0.722
0.8 0.2 0.9 0.5 0.833 0.833 0.833 0.833
0.2 0.8 0.9 0.5 0.595 0.595 0.595 0.595
2 0.5 0.5 0.167 0.75 0.313 0.313 0.313 0.313
0.8 0.2 0.167 0.75 0.212 0.212 0.212 0.212
0.2 0.8 0.167 0.75 0.500 0.500 0.500 0.500
3 0.5 0.5 0.617 0.894 0.447 0.578 0.673 0.490
0.8 0.2 0.617 0.894 0.412 0.541 0.634 0.456
0.2 0.8 0.617 0.894 0.521 0.658 0.756 0.565
4 0.5 0.5 0.277 0.643 0.404 0.358 0.334 0.404
0.8 0.2 0.277 0.643 0.361 0.317 0.293 0.362
0.2 0.8 0.277 0.643 0.505 0.458 0.434 0.504
5 0.5 0.5 0.277 1.555 0.469 0.433 0.414 0.469
0.8 0.2 0.277 1.555 0.379 0.336 0.314 0.380
0.2 0.8 0.277 1.555 0.712 0.699 0.693 0.712
In scenario 1, the underlying hazards are all constant (exponentially distributed event times), therefore the dependence
on time can be omitted. The cause-specific hazard ratios are given by 𝜃EP1 = 0.9 and 𝜃EP2 = 0.5. As expected, the all-cause
hazard ratio 𝜃CE = 0.722 lies in between these values. For weights w1 = 0.8,w2 = 0.2, the weighted all-cause hazard ratio
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given as 𝜃wCE = 0.833 is closer to 𝜃EP1 = 0.9, whereas for weights w1 = 0.2,w2 = 0.8 the weighted all-cause hazard ratio
𝜃wCE = 0.595 approaches 𝜃EP2 = 0.5.
Similar considerations hold true for scenario 2 where the underlying hazards are also constant. However, for scenario 2
the underlying hazards for EP1 are much larger than for EP2. Therefore, assigning weights of w1 = 0.8,w2 = 0.2 brings
𝜃wCE = 0.212 even closer to 𝜃EP1 = 0.167 whereas with inverse weighting w1 = 0.2,w2 = 0.8 the weighted effect 𝜃
w
CE = 0.5
is only slightly driven towards 𝜃EP2 = 0.75.
The same holds true for scenario 3 where again the hazards for EP1 are larger than for EP2 and thus have a higher
impact on the weighted effect. However, in scenario 3, the hazards in the intervention group are decreasing over time and
therefore the (weighted) hazard ratios are no longer constant in time. The magnitude of the effect now depends on the
time point where the averaged weighted all-cause hazard ratio shows the mean effect over time. However, the impact of
the different weights remain similar, that is, EP1 generally has a higher influence on the weighted all-cause hazard ratio
due to the larger hazards.
In scenario 4, the hazards in the intervention groups are increasing in time. Again, the hazards for EP1 are larger than
for EP2 and, as a consequence, EP1 generally has a higher influence on the weighted all-cause hazard ratio.
Finally, scenario 5 is the same as scenario 4 except that the group-specific hazards for EP2 are reversed. By this, EP1
shows an effect in favor of the intervention (at t = 5 the effect is given by 𝜃EP1 (5) = 0.277) whereas EP2 shows an effect in
favor of the control (𝜃EP1 (5) = 1.555). Interestingly, even with weightsw1 = 0.2,w2 = 0.8, the averaged weighted all-cause
hazard ratio given as ΘwCE(5) = 0.712 is mainly driven by EP1 and thus shows a clear effect in favor of the intervention.
This again can be explained by the fact that the underlying hazards are larger.
The high impact of the magnitude of the underlying hazards on the weighted all-cause hazard ratio is an important
difference to the weighted effect proposed by Lachin and Bebu20 where the log-transformed cause-specific hazard ratios
are weighted and thus the magnitude of the hazards has no influence. For real data sets, the magnitude of the hazards
will influence the observed number of events. It seems intuitive to assign a lower impact to a component with only a few
events, even if the corresponding cause-specific hazard ratio shows a large effect. If the number of events is low, the vari-
ability of the corresponding cause-specific effect is high and consequently the level of evidence is limited. Following this
argumentation, it is a favorable property that components with lower hazards also have a lower impact on the weighted
composite effect measure.
5.2 Comparison of the weighted all-cause hazard ratio to the proportion in favor
of treatment
The performance characteristics of the proportion in favor of treatment and the related win ratio approach for the specific
application to time-to-event outcomes are already well understood, compare, eg, the works of Bebu and Lachin or of
Rauch et al.17,18 The main problems related to these approaches were highlighted in Section 1. Therefore, we generally
do not recommend their use for time-to-event outcomes. However, the proportion in favor of treatment and the win ratio
are widely discussed in medical applications. We therefore performed additional simulations to compare the proportion
in favor of treatment to the weighted all-cause hazard ratio in order to better underline the differences.
Note, however, that the proportion in favor of treatment is calculated by comparing every patient from the intervention
to every patient from the control group and that the significance is tested bymeans of a permutation test, compare Section
3. Assessing the power of this nonparametric test again requires multiple repetitions of these steps. Therefore, the com-
putational effort to evaluate the power of the proportion in favor of treatment test is huge. As a consequence, we could
only investigated an artificial scenario with a small sample size and a medium number of permutation and simulation
runs. The obtained power values are therefore limited in precision. Note that the computational effort of the proportion
in favor of treatment test is a one of the drawbacks of this approach.
We consider a composite endpoint consisting of two componentswith different clinical relevance,whereEP1 defines the
more relevant endpoint and EP2 the less relevant component. The predefined weights for the weighted all-cause hazard
ratio are given as
w1 = 0.8, w2 = 0.2.
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TABLE 3 Simulated all-cause hazard ratio, weighted all-cause hazard ratio and proportion in favor of
treatment with related power values
Accrual Minimal FU ?̂?wCE (Power) ?̂?CE (Power) ?̂?EP𝟏 (Power) ?̂?EP𝟐(Power) ?̂?(Power)
3 5 1.44 (0.01) 2.09 (0.00) 0.93 (0.03) 2.48 (0.00) 0.14 (0.19)
2 10 1.44 (0.00) 2.06 (0.00) 1.03 (0.02) 2.28 (0.00) 0.21 (0.37)
Thus, there exist a large negative effect for the composite endpoint due to an even larger negative effect in the less
relevant component EP2 whereas the more important component EP1 shows a strong positive effect.
For these hazard assumptions, we randomly generated 1000 random samples with 40 patients per group. Thereby, uni-
form patient accrual was simulated with a fixed minimal follow-up. Two scenarios were considered to assess the impact
of the individual follow-up distribution on the different effect estimators: An accrual duration of 3 months with an addi-
tional minimal follow-up of 5 months and an accrual duration of 2 months with a follow-up of 10 months. For both
scenarios, the same starting seed was used for simulations to make the results of both scenarios more directly compa-
rable. For each sample, the proportion in favor of treatment was estimated as described in Section 3. The permutation
test was performed by randomly reassigning the group affiliations to the original complete data set and subsequently
calculating the point estimator Δ̂ as described above. We performed 500 repetitions of permutations to obtain the null
distribution of the estimator Δ̂. The corresponding hazard estimates within the two groups were obtained by fitting
Weibull-models with scale parameters fixed to 1 using the function survreg of the R package survival. The plug-in
estimator ?̂?wCE was obtained by substituting the resulting hazard estimates. The corresponding permutation test was
performed by randomly reassigning the group affiliations to the original complete data set and subsequently calcu-
lating the point estimator ?̂?wCE as described above. We performed 1000 repetitions of permutations to obtain the null
distribution of the estimator ?̂?wCE. The corresponding R code is provided as Supporting Information to ease application
in practice.
Table 3 shows the average effect estimates over all 1000 random samples and the estimated power values for the
weighted all-cause hazard ratio and the proportion in favor of treatment approaches.
It can be seen that ?̂?CE, ?̂?EP1 , and ?̂?EP2 are reasonably close to the true underlying hazard ratios. The deviation of ?̂?EP1
to 𝜃EP1 can be explained by the underlying small group-specific hazards, which increase the standard deviation of the
estimates. The weighted all-cause hazard ratio is estimated in mean as 1.44, which still defines a large negative effect
supporting a harmful effect of the intervention. However, the weighted effect is smaller than the unweighted effect, as
the contribution of the second component is smaller. Note that the less relevant component EP2 corresponds to larger
underlying hazards than forEP1. Therefore,EP2 has a higher impact on the overall effect even after weighting. In contrast,
the estimated mean proportion in favor of treatment is given by 0.14 in the scenario with the smaller follow-up duration.
This defines a clear effect in favor of the intervention group. Here, the large negative effect for EP2 has only a minor
influence as themajority of pairwise comparisons is either uninformative or favors the intervention group. This is because
a comparison with respect to the component of secondary relevance is only performed if no decision with respect to the
first component is possible. For the scenario with a longer follow up duration the estimated mean proportion in favor of
treatment is given by 0.21, which is an even larger effect in favor of the intervention whereas all other effect measures
remain basically unchanged. This can be explained by the fact that if the individual follow-up times are longer, thenmore
events of type EP1 are observed and thus more pairwise comparisons are based on considering EP1. This illustrates the
high sensitivity of the proportion in favor of treatment on the follow-up distribution. Note that in this simulation setting,
exponentially distributed event times were considered meaning that the hazards are constant in time. Therefore, the
dependence of the proportion of favor in treatment on the observational time is an unintuitive property, which makes its
interpretation quite difficult.
6 CLINICAL TRIAL EXAMPLES
We will now investigate the performance of the weighted all-cause hazard ratio approach in comparison to the common
all-cause hazard ratio which is assessed by the logrank test for the situation of the CAPRICORNTrial introduced earlier.12
We again consider the following hazard assumptions assuming exponentially distributed event timeswhich aremotivated
by the original observed and reported results13










To apply the weighted all-cause hazard ratio, the following weights are used as motivated above in Section 4.3
wDeath = 0.9,wHospital = 0.1.
To assess the robustness of the results under slightly different weights, we additionally investigate wDeath = 0.8,
wHospital = 0.2, and wDeath = 0.7,wHospital = 0.3. To directly compare the power of the permutation test to the power of
the Cox-model, we also consider wDeath = 0.5,wHospital = 0.5. Assuming exponentially distributed event times, the corre-
sponding weighted all-cause hazard ratios can be directly deduced and are provided in Table 4. Note that as we assume
exponentially distributed event times, the different effect are reported as constant parameters and the averaged weighted
all-cause hazard ratios were omitted.
For equal weights across the components (Table 4, line 1), the weighted all-cause hazard ratio is equivalent to the
standard all-cause hazard ratio by construction. From lines 2 to 4, it can be seen that the weighted all-cause hazard ratio
is reasonably robust against small changes in the weights. The weighted all-cause hazard ratio shows a larger effect for
increasing weight wDeath. This is because the component “death” shows a relatively large effect whereas the effect for the
component “cardiovascular hospital admission” slightly points in the adverse direction.
To investigate the performance of the corresponding point estimator proposed in (11) and of the permutation test, which
is used to assess the underlying test hypotheses provided in (14), we additionally performed a simulation study using
the software R. For the hazard assumptions specified above, we generated 10 000 random samples with 980 patients per
group. Thereby, uniform patient accrual was simulated within the first 24 months with an additional minimal follow-up
of 3 months. For each sample, the corresponding hazard estimates within the two groups were obtained by fitting
Weibull-models with scale parameters fixed to 1 using the function survreg of the R package survival. The plug-in
estimator ?̂?wCE was obtained by substituting the resulting hazard estimates. The permutation test was performed by ran-
domly reassigning the group affiliations to the original complete data set and subsequently calculating the point estimator
?̂?wCE as described above. We performed 1000 repetitions of permutations to obtain the null distribution of the estimator
?̂?wCE. The corresponding R code is provided as Supporting Information to ease application in practice.
Table 5 shows the average effect estimates over all 10 000 random samples and the estimated power values of the
permutation test and the corresponding Cox-models.
Generally, on average the different effect estimators approximate the true parameters provided in Table 4 very well.
When assigning equal weights to the components (line 1), the estimator for the weighted all-cause hazard ratio and for
the standard all-cause hazard ratio estimate the same parameter. The estimates are indeed nearly the same. The power of
the permutation test corresponding to the weighted all-cause hazard ratio is very close to the power of the corresponding
TABLE 4 Weighted all-cause hazard ratio for the
CAPRICORN trial
wDeath wHospital 𝜽wCE 𝜽CE 𝜽EP𝟏 𝜽EP𝟐
0.5 0.5 0.92 0.92 0.769 1.005
0.7 0.3 0.874 0.92 0.769 1.005
0.8 0.2 0.845 0.92 0.769 1.005
0.9 0.1 0.810 0.92 0.769 1.005




CE (Power) ?̂?CE (Power) ?̂?Death (Power) ?̂?Hospital(Power)
0.5 0.5 0.926 (0.177) 0.926 (0.174) 0.775 (0.482) 1.010 (0.021)
0.7 0.3 0.877 (0.366) 0.926 (0.175) 0.775 (0.482) 1.010 (0.021)
0.8 0.2 0.848 (0.436) 0.926 (0.175) 0.775 (0.482) 1.010 (0.021)
0.9 0.1 0.814 (0.467) 0.926 (0.175) 0.775 (0.482) 1.010 (0.021)
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Cox-model. The magnitude of the power, however, is low as the component “cardiovascular hospital admission” shows a
slight adverse effect. As a consequence, the combined effect is close to 1.
With increasing weight wDeath for the component “death,” the power of the permutation test increases and exceeds the
power of the Cox-model. This is due to the fact that the component “death” corresponds to a larger effect whereas the
component “cardiovascular hospital admission” shows a small adverse effect in terms of the corresponding cause-specific
hazard ratios, as pointed out above.
Generally, the weighted approach with reasonably chosen weights wDeath > wHospital > 0 might be preferred over the
standard unweighted Cox-model for the all-cause hazard ratio as a) it eases interpretation by taking into account the
different levels of relevance of the components and b) provides a power advantage for the specific parameter setting of
the CAPRICORN Trial. Whereas an interpretation benefit is given irrespective of the specific clinical trial scenario, the
power of the weighted approach depends on the underlying cause-specific hazards. There also exist situations, where the
weighted approach will have lower power compared to the standard Cox-model, eg, in the common situation when the
most relevant endpoint corresponds to the most rare event. To illustrate this situation, an additional clinical trial example
is investigated in the following. Note, however, that the primary intention of the weighted approach is to improve the
interpretation of the effect measure. Therefore, it is desirable that a weighted effect is shrunken when the most relevant
component only corresponds to a small effect and/or is based on a small number of events.
The RENAAL Trial was designed as a randomized, double-blind, placebo-controlled clinical trial with one interim
analysis to assess whether the angiotensin-II-receptor anatagonist losartan shows a therapeutic benefit for nephropathy
patients with type 2 diabetes.25,26 The primary endpoint was a composite time-to-first-event endpoint where the event
types were given as “death,” “end-stage renal disease,” or “doubling in the baseline serum creatinine concentration.”
Patients were randomized in a 1:1 allocation to receive either losartan or placebo. Recruitment duration was planned to
require 2 years, and the minimal patients' follow-up duration was chosen to be 3.5 years. The sample size calculation
was based on detecting a relative risk reduction of 0.2 in the 5-year cumulative event rate of the composite endpoint from
0.580 in the placebo group to 0.464 in the losartan group with 0.95 power at a global one-sided significance level of 0.025,
where the adjusted local significance level of the final analysis was 0.024. Assuming exponentially distributed event times,
the above effect corresponds to a hazard ratio of 0.72 (intervention versus control). The total sample size of 1513 patients
included a considerable number of patients due to a recruitment overrun.
The results of the RENAAL Trial where not provided by means of the corresponding hazard ratios, which would have
been the appropriate effect measure, but by means of the absolute and relative frequencies which ignores the censoring
distribution and issues of competing risks. Therefore, the published results should be interpreted with care. However, the
published results provide sufficient information to discuss general problems regarding the composite primary endpoint. A
number of 975 patients was recruited to the losartan group and 984 patients to the placebo group. The primary composite
endpoint was reached by 327 patients in the losartan group (0.435) as compared to 359 patients in the placebo group
(0.471), which corresponds to a relevant positive treatment effect. A detailed look into the single component effects reveals
a relevantly lower risk in the losartan group for the components “doubling in the baseline serumcreatinine concentration”
(162 events corresponding to an event rate of 0.216 in the losartan group versus 198 corresponding to a rate of 0.260
in the control group) and “end-stage renal disease” (147 events corresponding to an event rate of 0.196 in the losartan
group versus 194 events corresponding to an event rate of 0.255 in the control group), whereas in the particular harmful
component “death” a small adverse effect was observed (158 events corresponding to an event rate of 0.210 in the losartan
group versus 155 events corresponding to an event rate of 0.203 in the control group). From these results, we again deduced













It can be seen that the most relevant component “death” shows a small adverse effect. Thus, when assigning a higher
weight to the most relevant component death, the combined effect will be shrunken. This can be a situation where a
“benefit-risk assessment” to determine theweights as described in Section 4.3might be appropriate. The followingweights
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TABLE 6 Simulated weighted all-cause hazard ratio and power based on the results of the RENAAL Trial
wDeath wEndStage wDoubl ?̂?CE (Power) ?̂?
w
CE (Power) ?̂?Death (Power) ?̂?EndStage(Power) ?̂?Doubl (Power)
0.5 0.4 0.1 0.811 (0.806) 0.833 (0.585) 1.076 (0.014) 0.766 (0.667) 0.790 (0.531)
0.45 0.35 0.2 0.810 (0.804) 0.825 (0.698) 1.071 (0.012) 0.766 (0.665) 0.789 (0.540)
are chosen as starting values to investigate the weighted all-cause hazard ratio.
wDeath = 0.5, wEndStage = 0.4, wDoubl = 0.1.
As before, Table 6 shows the average effect estimates over 10 000 random samples as well as the estimated power values
of the permutation test and the corresponding Cox-models.
It can be seen that the power loss using the weighted all-cause hazard ratio is considerable. While the original all-cause
hazard ratio refers to a power value of 0.806 the power for the weighted all-cause hazard ratio is only 0.585. This might
impose the question how large the weight for the component “death” can be chosen without toomuch loss in power. Line
2 of Table 6 shows a constellation of weights which is similar to the starting values but yielding a power of approximately
0.7, which might still seem acceptable. These weights may thus be seen as an appropriate choice under “risk-benefit”
considerations. Note, again, that the rationale to introduce weights is not to increase the power but to improve the clinical
interpretation. While the CAPRICORN Trail illustrates a situation where the weights result in a power increase, the
RENAAL Trial shows that the gain in interpretation can also come along with a loss of power.
7 DISCUSSION
In this work, we presented a weighted all-cause hazard ratio as an alternative effect measure to the standard all-cause
hazard ratio to assess a composite time-to-first-event endpoint. The weights must be prespecified in the planning stage to
reflect the different levels of clinical relevance of the components. In contrast to other approaches proposed in the past,20
the weights are directly assigned to the individual cause-specific hazards and not to the (log-transformed) cause-specific
hazard ratios. By this, our approach defines a natural extension of the standard all-cause hazard ratio. In particular, both
effectmeasures are equivalent if equalweights are chosen across components. Theneweffectmeasure is a time-dependent
measure, which can either be reported for a specific follow-up time point or averaged over the observational period. The
theoretical investigations and the simulation study provided in Sections 5 and 6, respectively, illustrate the advantage of
our new approach: The weighted all-cause hazard ratio is more strongly influenced by components with high clinical
relevance whereas components of low relevance have a low impact. As a consequence, the weighted all-cause hazard
ratio defines a clinically more relevant effect measure. This, however, does not imply anything about the magnitude of
the effect. The weighted all-cause hazard ratio shows a higher effect than the standard all-cause hazard ratio whenever
the components of high clinical relevance show large effects. In contrast, the weighted all-cause hazard ratio will show
a smaller effect than the standard hazard ratio if treatment effects are only observed for components with low clinical
relevance. The intention to use theweighted all-cause hazard ratio is thus to improve the interpretation but not necessarily
to increase the power of the trial. Generally, an effect measure should primarily be chosen from a clinical perspective to
provide a meaningful quantification of the treatment effect.
The magnitude of the underlying cause-specific hazards additionally determines the size of the weighted all-cause
hazard ratio. If a single component shows a large effect (in terms of the cause-specific hazard ratio) but the underly-
ing cause-specific hazards are small, then this effect relies on only a few events. Therefore, it is desirable that small
cause-specific hazards have a lower impact on the weighted effect than large cause-specific hazards. As pointed out in
Section 5, the impact of the magnitude of the underlying hazards on the weighted all-cause hazard ratio is an impor-
tant difference to the approach proposed by Lachin and Bebu20 where the magnitude of the individual hazards has no
influence but only the magnitude of the individual hazard ratios.
Our new approach can easily be extended to take account of covariates by substituting the covariate-adjusted estimates
of the cause-specific hazards from the corresponding survival model. Note, however, that in the presence of covariates,
the standard all-cause hazard ratio estimated from the Cox-model and the weighted all-cause hazard ratio might differ
even in the case of equal weights across components, as covariates are modeled differently in both approaches. A more
detailed investigation of this issue is topic of an ongoing work. Moreover, multiple events per patient can be considered by
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additionally including weighted hazards for the transition between a first and a second event or between any subsequent
events.
A potential drawback of our method is that a parametric survival model is required to identify the underlying
cause-specific hazards. However, considering the large number of possible parametric survival models, this is not a strong
restriction with respect to flexibility. However, the choice of an adequate parametric survival model in the planning stage
defines a major challenge. Assessing the robustness of the estimators under misspecifications of the underlying survival
model is one of the aims of our ongoing research.To partly address this issue, we additionally presented a nonparametric
estimator for the weighted all-cause hazard ratio for the special case of equal baseline-hazards across the components. It
may be seen as another disadvantage of our approach that the distribution of the test statistic cannot directly be deduced
and hence nonparametric conditional tests such as the permutation test have to be applied for hypotheses testing.We have
implemented the permutation test for the weighted all-cause hazard ratio in the software R and provide the source code
as Supporting Information. By this, application of our method in practice can be done with minimal effort for each para-
metric model where hazard functions are estimable. Moreover, the permutation test offers the advantage that it remains
valid under misspecifications of the underlying survival model. Even if the point estimator is biased, the permutation test
still defines a valid test strategy for this slightly modified effect measure.
Generally, weighted approachesmight be also defined using additive survivalmodels. Using aweighted average of com-
ponent effect measures derived from an additive model has the advantage that the underlying distribution can be easily
deduced and thus a parametric test can be defined. Moreover, using an additive model would not require the specification
of parametric survival models to identify the individual hazards. An important drawback of this appealing alternative
is, however, that additive models are rarely met in practice and a direct comparison to the standard Cox-model for the
all-cause hazard ratio is not possible. Still, this approach is an interesting topic for future research.
We additionally provided a small simulation study to illustrate the difference between the weighted all-cause hazard
ratio and the commonly cited proportion in favor of treatment proposed by Buyse.16 The results show that the proportion
in favor of treatment strongly depends on the individual follow-up distribution and therefore does not properly defines
a weighting approach with predefined relevance weights. These results are in common with the conclusions from other
authors,17,18 which support the recommendation that the proportion in favor of treatment might not be a good effect
measure when applied to several time-to-event endpoints.
Although composite endpoints most often correspond to time-to-event variables, there also exist situations where
a binary composite endpoint is considered. The presented approach might be generalized to define a corresponding
weighted effect measure for binary composite endpoints. A related weighting approach for binary composite endpoints
was also proposed by Duc and Wolbers.14
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